



Update on MP0712 program

- New mechanism of action data
- Initial human images
- Outlook on Phase 1/2a study

Patrick Amstutz, CEO

Webcast call following TRP 2025 presentation

November 12, 2025



Disclaimer

This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2025. These statements may be identified by words such as "aim", "anticipate", "expect", "guidance", "intend", "outlook", "plan", "potential", "will" and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners' actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at www.molecularpartners.com. In addition, this presentation contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future.

Any forward-looking statements speak only as of the date of this presentation and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.


Making Alpha Therapies a Reality with DARPins and ^{212}Pb



MOLECULAR PARTNERS
PIONEERS of DARPIN THERAPEUTICS


ORANO MED

PIONEERS of TARGETED ALPHA THERAPY




FULL VALUE CHAIN PARTNERSHIP:

- ✓ World class technologies & capabilities combined
- ✓ DARPins as ideal vectors for radiopharmaceuticals
- ✓ ^{212}Pb as potent therapeutic payload, proven clinical efficacy




MP0712: Potent Efficacy at Clinically-Relevant Dose in Mice

High Tumor Accumulation (Tumor > Kidney)






Reduction of Established Tumors





DLL3 targeting “Why do we see High Tumor Uptake, Despite the low Copy Number”


High Tumor Accumulation (MP0712: Tumor > Kidney)




Low DLL3 density on tumor cells (of <1000 receptors/cell)



MP0712-DLL3 DARPin is Rapidly Internalized and Accumulates Intracellularly in DLL3-expressing Cells *in vitro*




Surface-bound DLL3-DARPin is rapidly internalized into SHP-77 human SCLC cells*




DAPI DARPin EEA1

Internalized DLL3-DARPin shows significant co-localization to the endosomal compartment in HEK-hDLL3 cells**



DLL3-DARPin accumulates in HEK-hDLL3 cells over time (beyond the bound fraction at saturation)*


Hypothesis: Free Surface DLL3 is Continually Replenished for Binding and Internalization of MP0712



MP0712 – format selection:
Optimized half-life and DARPin binder to exploit internalization & replenishment of DLL3 for radiopayload accumulation in SCLC cells

MP0712 Development Pathway


1. Imaging



Named Patient Access Program:

- Imaging and dosimetry with ^{203}Pb
 - Option for treatment with ^{212}Pb
- Request from NuMeRI, Pretoria, South Africa**

2. Treatment



Phase 1/2a Study:

- Safety of ^{212}Pb
- Efficacy signals
- Includes an imaging and dosimetry step with ^{203}Pb

SPECT/CT Imaging of ^{203}Pb -MP0712 in SCLC: A Case Example from a Named Patient Access Program in SA (Patient #3)

Patient characteristics


- 69-year-old male (smoker)
- Small cell neuroendocrine carcinoma of the lung
- Stage III at referral, primary tumor located at superior mediastinum

Treatment history

- Radiotherapy and chemotherapy

Dosing & Result


- 5.1 mCi of ^{203}Pb -MP0712
- Stage IV by MP0712 - SPECT with 4 liver mets



➤ Initial high blood pool, followed by specific uptake in primary and metastatic lesions over time, and limited accumulation in healthy organs in line with MP0712 MoA


MP0712 Phase 1/2a Study for SCLC and other NECs

- First-in-Human, US multicenter, Phase 1/2a study of MP0712 monotherapy
- Patients with small cell lung cancer (SCLC) and other neuro-endocrine cancers (NECs)
 - Every patient will be imaged (^{203}Pb) before treatment (^{212}Pb)
 - Patient pre-selection on DLL3 expression: not planned for SCLC and LC NEC of lung, foreseen for epNEC



* Evaluable patients (Bayesian Logistic Regression Model guided dose escalation)

MP0712 - Why DLL3 Targeted Radio Therapy for SCLC



Radio Therapy (MP0712)

- Phase 0/I
- SCLC highly radio sensitive
- Manageable side effects
- Combinable with other MoAs


T-Cell engagers

- Tarlatamab approved
- 40% RR
- DoR: 9.7 months
- Substantial side effects

Antibody-Drug Conjugates

- Phase I/II
- 70% RR
- Risk of chemo-resistance
- Manageable side effects

Conclusions & Outlook



MP0712: ^{212}Pb x DLL3 Radio-DARPin therapeutic candidate for SCLC


- Strong pre-clinical data with attractive BioD, efficacy & safety profile
- High tumor uptake leveraging rapid internalization & replenishment of DLL3
- Initial human images* show specific uptake in primary & metastatic tumor lesions supporting intended MoA

Outlook

- Full ^{203}Pb -MP0712 compassionate care imaging & dosimetry data at TWC 2026
- MP0712 Phase 1 IND application filed, trial initiation expected before year end 2025
- Initial data from Phase 1 in 2026

Acknowledgments

Team at Molecular Partners AG



NuMeRI Team

Mike Sathekge
Joseph Kabunda
Honest Ndlovu



Orano Med Team



Julien Torgue
Amal Saidi
Aaron Schatzmann
Tania Stallons
Amy Wong
Federico Rojas
Amanda Reyes
Jessica Johnson
Rob Chastain
Haley Sprague
Volker Wagner &
clinical team

Patients and their Families